Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Elzasonan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | BCL2A1 | Q16548 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | BID | P55957 | 1/20 | 0.43 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elzasonan SCHEMBL5159337 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 | |
| Elzasonan SCHEMBL5159647 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 | |
| Elzasonan SCHEMBL29379325 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 | |
| Elzasonan SCHEMBL1649875 | 0.98 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 | |
| Elzasonan SCHEMBL4604000 | 0.98 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 | |
| Elzasonan SCHEMBL4604009 | 0.98 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 | |
| Elzasonan SCHEMBL4604005 | 0.98 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 | |
| SCHEMBL5160797 | 0.96 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 | |
| SCHEMBL5160805 | 0.96 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 | |
| SCHEMBL5606554 | 0.91 | BCL2A1 (0.44) | SLC6A2SLC6A4SLC6A3HTR1ABCL2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007026219-A2 | COMBINATIONS OF A 5-HT1B ANTAGONIST WITH A NORADRENALIN RE-UPTAKE INHIBITOR OR A SEROTONIN NORADRENALIN REUTAKE INHIBITOR FOR TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2007-03-08 | — | — | WO | claimed |
| EP-1753460-A2 | COMBINATION OF ATYPICAL ANTIPSYCHOTICS AND 5-HT1B RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1737466-A1 | COMBINATION OF y-AMINOBUTYRIC ACID MODULATORS AND 5-HT-1b RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2007-01-03 | — | — | EP | claimed |
| EP-1703918-A2 | COMBINATION OF CRF ANTAGONISTS AND 5-HT 1B RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2006-09-27 | — | — | EP | claimed |
| US-20060052373-A1 | Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC | 2006-03-09 | — | — | US | claimed |
| US-20060009448-A1 | Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]thiomorpholin-3-one | PFIZER INC. | 2006-01-12 | — | — | US | claimed |
| WO-2005113526-A2 | METABOLITES OF 4-(3,4-DICHLORO-PHENYL)-2-[2-(4-METHYL-PIPERAZIN-1-YL)-BENZYLIDENE]-THIOMORPHOLIN-3-ONE | PFIZER PRODUCTS INC. (US) | 2005-12-01 | — | — | WO | claimed |
| US-20050256112-A1 | Combination of atypical antipsychotics and 5HT-1B receptor antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| WO-2005107808-A2 | COMBINATION OF ATYPICAL ANTIPSYCHOTICS AND 5-HT1B RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-17 | — | — | WO | claimed |
| WO-2005082372-A1 | COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-09-09 | — | — | WO | claimed |
| US-20020147194-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-10-10 | — | — | US | claimed |
| US-6423708-B1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC | 2002-07-23 | — | — | US | claimed |
| US-20020091117-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. | 2002-07-11 | — | — | US | claimed |
| US-20020091118-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. | 2002-07-11 | — | — | US | claimed |
| US-20020091119-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-07-11 | — | — | US | claimed |
| US-20020072519-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-06-13 | — | — | US | claimed |
| US-6380186-B1 | PSYCHOTHERAPEUTIC AGENTS | PFIZER INC | 2002-04-30 | — | — | US | claimed |
| US-20020049211-A1 | Combination treatment for depression and anxiety | SOBOLOV-JAYNES SUSAN BETH (US) | 2002-04-25 | — | — | US | claimed |
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER PRODUCTS INC. | 2002-04-25 | — | — | US | claimed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091118-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | MRPL21, ARAF, ARL1 | SLC6A2 4351/4885SLC6A4 4583/4885SLC6A3 4294/4885 |
| US-20020091119-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | SLC6A2 4351/4885SLC6A4 4583/4885SLC6A3 4294/4885 |
| US-20060009448-A1 | Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]thiomorpholin-3-one | OPRM1, PNMT, OPRK1 | SLC6A2 155/4885SLC6A4 69/4885SLC6A3 24/4885 |
| US-20020147194-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | SLC6A2 4351/4885SLC6A4 4583/4885SLC6A3 4294/4885 |
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | SLC6A2 4180/4885SLC6A4 4503/4885SLC6A3 4113/4885 |
| US-20060052373-A1 | Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides | DRD2, OPRL1, SLC6A3 | SLC6A2 20/4885SLC6A4 107/4885SLC6A3 3/4885 |
| US-20020049211-A1 | Combination treatment for depression and anxiety | HTR1A, HTR1D, HTR5A | SLC6A2 39/4885SLC6A4 36/4885SLC6A3 81/4885 |
| US-20050256112-A1 | Combination of atypical antipsychotics and 5HT-1B receptor antagonists | HTR1B, HTR2B, HTR3B | SLC6A2 59/4885SLC6A4 26/4885SLC6A3 44/4885 |
| US-20020072519-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | SLC6A2 4351/4885SLC6A4 4583/4885SLC6A3 4294/4885 |
| US-20020091117-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | MRPL21, ARAF, ARL1 | SLC6A2 4351/4885SLC6A4 4583/4885SLC6A3 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.